Rifampicin has a Profound Effect on the Pharmacokinetics of Oral S‐Ketamine and Less on Intravenous S‐Ketamine
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Low‐dose ketamine is currently used in several acute and chronic pain conditions as an analgesic. Ketamine undergoes extensive metabolism and is thus susceptible to drug–drug interactions. We examined the effect rifampicin, a well‐known inducer of many cytochrome P450 (CYP) enzymes and transporters, on the pharmacokinetics of intravenous and oral S‐ketamine in healthy volunteers. Eleven healthy volunteers were administered in randomized order 600 mg rifampicin or placebo orally for 6 days in a four‐session paired cross‐over study. On day 6, S‐ketamine was administered intravenously (0.1 mg/kg) in the first part of the study and orally (0.3 mg/kg) in the second part. Plasma concentrations of ketamine and norketamine were measured up to 24 hr and behavioural and analgesic effects up to 12 hr. Rifampicin treatment decreased the mean area under the plasma ketamine concentration–time curve extrapolated to infinity (AUC 0–∞) of intravenous and oral S‐ketamine by 14% (p = 0.005) and 86% (p < 0.001), respectively. Rifampicin decreased greatly the peak plasma concentration of oral S‐ketamine by 81% (p < 0.001), but shortened only moderately the elimination half‐life of intravenous and oral S‐ketamine. Rifampicin decreased the ratio of norketamine AUC 0–∞ to ketamine AUC 0–∞ after intravenous S‐ketamine by 66%, (p < 0.001) but increased the ratio by 147% (p < 0.001) after the oral administration of S‐ketamine. Rifampicin profoundly reduces the plasma concentrations of ketamine and norketamine after oral administration of S‐ketamine, by inducing mainly its first‐pass metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The use of analogue scales in rating subjective feelings
BOND, A., & LADER, M. (1974) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1974.tb02285.x · Cited by 1,972
Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans
Clements, J. A., Nimmo, W. S., & Grant, I. S. (1982) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600710516 · Cited by 420
Cited by
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
“Oral bioavailability of (S)-ketamine was calculated to be 8%–11% (Peltoniemi et al., 2012; Fanta et al., 2015), consistent with the greater first-pass metabolism of (S)-ketamine relative to (R,S)-ketamine.”
BackgroundKetamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy
Peltoniemi, M. A., Hagelberg, N. M., Olkkola, K. T., & Saari, T. I. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0383-6 · Cited by 672
Self-citationEsketamine: new hope for the treatment of treatment-resistant depression? A narrative review
Salahudeen, M. S., Wright, C. M., & Peterson, G. M. (2020) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098620937899 · Cited by 72
Role of Cytochrome P4502B6 Polymorphisms in Ketamine Metabolism and Clearance
Rao, L. K., Flaker, A. M., Friedel, C. C., & Kharasch, E. D. (2016) · Anesthesiology · doi:10.1097/aln.0000000000001392 · Cited by 67
Weiss, M., & Siegmund, W. (2022) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.993 · Cited by 13
Metadata
- Authors
- Peltoniemi, M. A., Saari, T. I., Hagelberg, N. M., Laine, K., Kurkinen, K. J., Neuvonen, P. J., & Olkkola, K. T.
- Venue
- Basic & Clinical Pharmacology & Toxicology
- Publisher
- Wiley
- Published
- 2012-06-27
- Volume
- 111
- Issue
- 5
- Pages
- 325-332
- ISSN
- 1742-7835 (ISSN-L)
- 1742-7843
- OpenAlex
- W2072055545
- Cited by
- 56
- References
- 2
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rifampicin has a Profound Effect on the Pharmacokinetics of Oral S‐Ketamine and Less on Intravenous S‐Ketamine. https://app.cochat.ai/papers/10.1111/j.1742-7843.2012.00908.x
- The paper
- Peltoniemi, M. A., Saari, T. I., Hagelberg, N. M., Laine, K., Kurkinen, K. J., Neuvonen, P. J., & Olkkola, K. T. (2012). Rifampicin has a Profound Effect on the Pharmacokinetics of Oral S‐Ketamine and Less on Intravenous S‐Ketamine. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/j.1742-7843.2012.00908.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.